Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives
By Ben Glickman
Pulmatrix will close a study of a potential treatment for a fungal lung infection as it prioritizes limiting cash burn and pursuing strategic alternatives.
The biopharmaceutical company said that Cipla, its partner in developing the treatment, would take responsibility for the development of PUR1900 for Allergic Bronchopulmonary Aspergillosis, a fungal infection in the lungs, under an amendment to the two companies' agreement.
Cipla and Pulmatrix agreed to stop enrollment in a Phase 2b study of PUR1900 and close the study.
Pulmatrix will receive 2% royalties on sales of Pulmazole in the Cipla territory, which is defined under the agreement as the area in which Cipla can exclusively develop and commercialize PUR1900.
Pulmatrix's Chief Executive Ted Raad said stopping the study and implementing other cost-saving initiatives was expected to extend the company's cash runway to the first quarter of 2026.
The company will pursue strategic alternatives as it winds down the study as part of a focus on maximizing shareholder value.
As of Dec. 31, 2023, the company had cash on hand of about $19 million.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 08, 2024 09:38 ET (14:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks